Key Events This Week
09 Mar: Stock opens at Rs.1,286.40 amid broad market weakness
10 Mar: Intraday high surge of 3.23% to Rs.1,326.50; Mojo Grade downgraded to Sell
11 Mar: Price rebounds with 2.28% gain to Rs.1,325.50; technical momentum shifts sideways
12-13 Mar: Price retreats, closing week at Rs.1,293.00 (-0.51% and -1.95% respectively)
09 March 2026: Weak Market Start Amid Sensex Decline
Dr Reddys Laboratories Ltd opened the week at Rs.1,286.40, down 1.34% from the previous Friday’s close of Rs.1,303.90. This decline occurred alongside a sharp Sensex drop of 1.91%, reflecting broad market weakness. The stock’s volume was moderate at 49,642 shares, indicating cautious investor sentiment amid a challenging macroeconomic backdrop. The initial fall set a subdued tone for the week, with the stock trading near the lower end of its recent range.
10 March 2026: Intraday Surge and Downgrade Shake Market Sentiment
On 10 March, Dr Reddys staged a notable intraday recovery, surging 3.23% to an intraday high of Rs.1,326.50. The stock closed at Rs.1,313.90, a 2.14% gain on the day, outperforming the Sensex which rose 1.30%. This rebound followed two consecutive days of decline and brought the stock close to its 52-week high of Rs.1,377.95, signalling renewed buying interest.
However, this positive price action was tempered by a significant downgrade from MarketsMOJO, which lowered the stock’s Mojo Grade from Hold to Sell on 9 March 2026. The downgrade reflected concerns over deteriorating technical indicators and disappointing recent quarterly financial results, including an 18.3% decline in Profit Before Tax and a 16.2% drop in Profit After Tax. Despite strong long-term fundamentals such as a low debt-to-equity ratio of 0.01 and a healthy ROE of 15.78%, the downgrade highlighted near-term risks.
The technical momentum also shifted to a mildly bearish stance, with daily moving averages turning negative and mixed signals from MACD and KST indicators. The stock’s Price to Book ratio of 3 and a high PEG ratio of 5.3 further underscored valuation concerns amid modest profit growth.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
11 March 2026: Price Rebounds as Technical Momentum Shifts Sideways
The stock continued its recovery on 11 March, closing at Rs.1,325.50, up 0.88% from the previous day’s close. Intraday volatility was evident, with a trading range between Rs.1,281.90 and Rs.1,329.00. This price appreciation marked a shift in technical momentum from mildly bearish to sideways, suggesting a pause in the recent downward trend.
Technical indicators presented a mixed picture: the weekly MACD remained bullish, while the monthly MACD stayed mildly bearish. Bollinger Bands on weekly and monthly charts showed mild bullishness, and the KST indicator was mildly bullish weekly but bearish monthly. The Relative Strength Index (RSI) hovered in neutral territory, indicating neither overbought nor oversold conditions. Volume-based indicators such as On-Balance Volume (OBV) showed no clear trend, reflecting uncertainty among traders.
Despite the cautious technical signals, Dr Reddys outperformed the Sensex, which declined 1.36% on the day. The stock’s resilience amid broader market weakness highlighted its relative strength within the Pharmaceuticals & Biotechnology sector.
12-13 March 2026: Price Retreats Amid Market Downturn
On 12 March, the stock slipped 0.51% to Rs.1,318.75, followed by a sharper decline of 1.95% on 13 March, closing the week at Rs.1,293.00. These declines occurred alongside significant Sensex falls of 0.66% and 2.29% respectively, as broader market pressures intensified. The stock’s volume surged to 72,610 shares on 13 March, indicating increased trading activity amid the sell-off.
The retreat in price reflected the ongoing technical caution and the impact of the earlier downgrade. The stock remained above its 52-week low of Rs.1,025.90 but below recent highs, suggesting consolidation within a defined range. The weekly performance showed a modest loss of 0.84%, but this was a relative outperformance compared to the Sensex’s 4.87% decline over the same period.
Why settle for Dr Reddys Laboratories Ltd? SwitchER evaluates this large-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-09 | Rs.1,286.40 | -1.34% | 34,557.39 | -1.91% |
| 2026-03-10 | Rs.1,313.90 | +2.14% | 35,005.20 | +1.30% |
| 2026-03-11 | Rs.1,325.50 | +0.88% | 34,529.78 | -1.36% |
| 2026-03-12 | Rs.1,318.75 | -0.51% | 34,300.49 | -0.66% |
| 2026-03-13 | Rs.1,293.00 | -1.95% | 33,516.43 | -2.29% |
Key Takeaways
Positive Signals: Despite a modest weekly decline of 0.84%, Dr Reddys Laboratories Ltd outperformed the Sensex by 4.03%, demonstrating relative resilience amid broad market weakness. The stock’s ability to rebound sharply on 10 and 11 March, touching an intraday high near Rs.1,326.50, highlights underlying buying interest. Long-term fundamentals remain solid, with low debt, healthy ROE of 15.78%, and steady sales growth of 13.12% annually.
Cautionary Signals: The downgrade to a Sell rating by MarketsMOJO reflects concerns over deteriorating technical momentum and disappointing quarterly profit declines of over 16%. Technical indicators present a mixed outlook, with daily moving averages turning mildly bearish and monthly MACD signalling caution. The high PEG ratio of 5.3 suggests valuation pressures amid modest earnings growth. Increased volatility and volume spikes towards week-end indicate uncertainty among investors.
Conclusion
The week ending 13 March 2026 was a mixed one for Dr Reddys Laboratories Ltd, characterised by volatile price movements, a significant downgrade, and shifting technical momentum. While the stock managed to outperform the Sensex and demonstrated resilience through intraday rallies, the downgrade to Sell and weakening technical indicators signal caution. Investors should weigh the company’s strong long-term fundamentals against near-term earnings challenges and technical uncertainties. The stock appears to be in a consolidation phase, with potential for either recovery or further correction depending on upcoming market developments and financial results.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
